A5077463490- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- Cancer Immunotherapy and Biomarkers
- Medical Imaging Techniques and Applications
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Cancer Cells and Metastasis
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Cellular Mechanics and Interactions
- Nanoparticle-Based Drug Delivery
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Chronic Lymphocytic Leukemia Research
- Chemotherapy-induced cardiotoxicity and mitigation
- Peptidase Inhibition and Analysis
- 3D Printing in Biomedical Research
Hospital Universitario Ramón y Cajal
2015-2024
GEICAM – Spanish Breast Cancer Group
2016-2024
Instituto Ramón y Cajal de Investigación Sanitaria
2018-2024
Instituto de Investigación Marqués de Valdecilla
2024
Instituto de Biomedicina y Genética Molecular de Valladolid
2023
Universidad de Valladolid
2023
Instituto Cajal
2016-2023
Hiroshima University Hospital
2023
Roche (Switzerland)
2015-2021
International Breast Cancer Study Group
2021
BackgroundThe ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC).Patients and MethodsExteNET was a multicenter, randomized, double-blind, phase III of 2840 HER2+ eBC after neoadjuvant/adjuvant trastuzumab-based therapy. Patients were stratified by HR status...
Purpose To test whether combining bevacizumab, an anti–vascular endothelial growth factor treatment, with endocrine therapy (ET) could potentially delay the emergence of resistance to ET. Patients and Methods A multicenter, randomized, open-label, phase III, binational (Spain Germany) study added bevacizumab (15 mg/kg every 3 weeks) ET (ET-B; letrozole or fulvestrant) as first-line in postmenopausal patients human epidermal receptor 2 (HER2) –negative hormone receptor–positive advanced...
To assess palbociclib in combination with trastuzumab or without endocrine therapy patients HER2-positive advanced breast cancer.PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had received 2-4 prior lines of anti-HER2-based regimens. Treatment consisted 200 mg daily for 2 weeks and 1 week off plus trastuzumab. The study was based on Simon two-stage design comprising three cohorts: estrogen receptor (ER)-negative (cohort A), ER-positive B1), letrozole B2). were...
The HER2-enriched (HER2-E) subtype within HER2-positive (HER2+) breast cancer is highly addicted to the HER2 pathway. However, ∼20-60% of HER2+/HER2-E tumors do not achieve a complete response following anti-HER2 therapies. Here we evaluate gene expression data before, during and after neoadjuvant treatment with lapatinib trastuzumab in PAMELA trial cell lines. Our results reveal that dual blockade HER2-E disease induces low-proliferative Luminal A phenotype both patient's vitro models....
Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients tumors that have progressed on endocrine therapy and/or are not eligible had limited treatment options beyond chemotherapy. Antibody-drug conjugates a novel and promising class in this setting. Datopotamab deruxtecan (Dato-DXd) consists of TROP2-directed humanized IgG1 monoclonal antibody attached via serum-stable cleavable linker to topoisomerase I inhibitor payload. TROPION-Breast01...
PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ cancer, who had disease progression on endocrine therapy, for whom therapy was...
Abstract Background: The global, phase 3 TROPION-Breast01 trial (NCT05104866) assessed the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) compared with investigator’s choice of chemotherapy (ICC) in patients (pts) inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2‒) breast cancer (BC). Primary results were presented at ESMO 2023 (Bardia A, et al. LBA11). Here we report expanded data from TROPION-Breast01. Methods: Pts aged ≥18 years...
The objective of this study was to determine the conversion rate human epidermal growth factor receptor 2 (HER2), estrogen (ER) and progesterone (PR) between primary tumors metastatic lesions in advanced breast cancer. Patients with suspected diagnosis locally recurrent or cancer, either at first relapse after successive disease progressions, who had an appropriately preserved sample from a tumor were scheduled for biopsy lesion, included. Blinded determinations status on paired samples...
Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 adjuvant trial to investigate the integration of capecitabine into a regimen epirubicin and docetaxel for node-positive early BC.Patients with operable BC (T1-3/N1-3) were eligible. After surgery, 1,384 patients randomly assigned receive plus cyclophosphamide (EC; 90 600 mg/m(2), respectively, × four cycles), followed by (100 mg/m(2) cycles; EC-T) or (ET; 75 (1,250 twice day on days 1 14, ET-X); all regimens...
Abstract Despite their recognised role in HER2-positive (HER2+) breast cancer (BC), the composition, localisation and functional orientation of immune cells within tumour microenvironment, as well its dynamics during anti-HER2 treatment, is largely unknown. We here investigate changes tumour-immune contexture, assessed by stromal tumour-infiltrating lymphocytes (sTILs) multiplexed spatial cellular phenotyping, treatment with lapatinib-trastuzumab HER2+ BC patients (PAMELA trial). Moreover,...
IntroductionPatients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding vaccines immunogenicity in this population is crucial for adequately planning programs. The ONCOVac study aimed to comprehensively assess the mRNA-1273 vaccine terms humoral cellular response.MethodsWe conducted a prospective, single-center including patients solid tumours treated cyclin-dependent kinases 4 6 inhibitors (CDK4/6i), immunotherapy (IT) or...
Abstract Background Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity restoring inhibition of AKT by everolimus. This study evaluated the addition xentuzumab everolimus exemestane in patients with advanced breast cancer non-visceral disease. Methods double-blind, randomised, Phase II was undertaken female hormone-receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative disease who had received prior endocrine...
BackgroundThe potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative endocrine-sensitive advanced breast cancer (ABC) patients remains uncharacterized.Patients and methodsIn this randomized (1:1), double-blind, phase II study, postmenopausal women with HR-positive, HER2-negative ABC de novo metastatic disease or those who relapsed after >12 months adjuvant endocrine therapy received...
Purpose: We previously detected promising efficacy of neoadjuvant nintedanib (a multityrosine kinase inhibitor, TKI) in early HER2-negative breast cancer. In a preclinical study, we monitored stromal hypoxia with 18F-fluoromisonidazole-positron emission tomography (18F-FMISO-PET); found that reoxygenation tumors (or lack it) during window-of-opportunity (WoO) treatment TKIs correlated the benefit from TKI-plus-chemotherapy combinations. studied predictive role 18F-FMISO-PET for TKI setting...
519 Background: HRD status is significantly associated with a higher rate of response to neoadjuvant platinum-based therapy and improved PFS following adjuvant doxorubicin cyclophosphamide (AC) in TNBC. We assessed the prognostic predictive role assay for platinum PARP inhibitor BrighTNess. Methods: 634 stage II-III TNBC pts were randomized 2:1:1 to: Arm A: Paclitaxel (T) q wk x 12 + carboplatin (P) (AUC 6) q3 4 veliparib (TPV) - > AC q2-3 4; B: T P placebo (TP) AC; or C: dual AC. was...
Abstract Background The biological effect of oral metronomic vinorelbine (mVNB) alone or in combination with endocrine therapy patients hormone receptor-positive (HR+)/HER2-negative breast cancer has been scarcely addressed. Methods Postmenopausal women untreated stage I–III HR+/HER2-negative were randomized (1:1:1) to receive 3 weeks letrozole (LTZ) 2.5 mg/day, mVNB 50 mg days/week, the combination. primary objective was evaluate, within PAM50 Luminal A/B disease, if anti-proliferative...
Abstract Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti‐PD‐1 therapy cancer models. This dose‐escalation/expansion study investigated the safety, pharmacokinetics, pharmacodynamics, preliminary efficacy of mivavotinib plus nivolumab patients advanced solid tumors. Patients received oral 60–100 mg once‐daily intravenous 3 mg/kg on days 1 15 28‐day cycles until disease progression...